How to Order

CABENUVA





CABENUVA 600-mg/900-mg kit

(for use in every-2-month and once-monthly dosing schedules)*

Two extended-release injectable suspensions: cabotegravir 600 mg/3 mL & rilpivirine 900 mg/3 mL

NDC – 49702-240-15

CABENUVA 400-mg/600-mg kit

(for use in once-monthly dosing schedule)*

Two extended-release injectable suspensions: cabotegravir 400 mg/2 mL & rilpivirine 600 mg/2 mL

NDC – 49702-253-15

*Please click for Prescribing Information for CABENUVA for more information on dosing and administration.

INDICATION

CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Do not use CABENUVA in patients with previous hypersensitivity reaction to cabotegravir or rilpivirine
- Do not use CABENUVA in patients receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, systemic dexamethasone (>1 dose), and St John's wort

Please see additional Important Safety Information throughout and click for full Prescribing Information for CABENUVA.

Get support from ViiVConnect
Visit ViiVConnect.com

Call to speak to an Access Coordinator
1-844-588-3288 (toll-free)
Monday-Friday, 8AM-11PM (ET)

ViiVConnect

CABENUVA
cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
extended-release injectable suspensions

Available via specialty pharmacy or Buy & Bill

Specialty pharmacy network for CABENUVA

The following specialty pharmacies currently participate in the specialty pharmacy network for CABENUVA. Fulfillment may vary based on individual health insurance plans.

Accredo Health Group, Inc
Phone: (877) 222-7336
Fax: (888) 302-1028
Hours of Operation: Monday-Friday: 7AM-10PM (CT)
Saturday: 7AM–4PM (CT) | Sunday: Closed

AHF Pharmacy
Phone: (877) 429-0708
Fax: (833) 814-1322
Hours of Operation: Monday-Friday: 8AM-8PM (ET)

AllianceRx Walgreens Prime
Phone: (888) 347-3416
Fax: (866) 889-1510 | (877) 231-8302
Hours of Operation: Monday-Friday: 8AM-8PM (ET)
Saturday: 8:30AM-5PM (ET) | Sunday: Closed

Avita Pharmacy
Phone: (469) 592-2000 |
Fax: (877) 234-0067
Hours of Operation:
Monday-Friday: 8AM-5PM (CT)
Saturday: Closed | Sunday: Closed

Coordinated Care Network
Phone: (877) 349-6330
Fax: (877) 770-4107
Hours of Operation: Monday-Friday: 8:30AM-5PM (ET)
Saturday-Sunday: Closed

Curant Health
Phone: (866) 437-8040
Fax: (866) 437-8411
Hours of Operation: Monday-Friday: 8:30AM-5:30PM (ET)
Saturday-Sunday: Closed

CVS Specialty
Phone: (800) 237-2767
Fax: (800) 323-2445
Hours of Operation: Monday-Friday: 7:30AM-7:30PM (CT)
Saturday-Sunday: Closed

Fairview Specialty
Phone: (612) 672-7516
Fax: (612) 672-5330
Hours of Operation: Monday-Friday: 8AM-7PM (CT)
Saturday: 8AM-4PM (CT) | Sunday: Closed

Humana Specialty Pharmacy
Phone: (800) 486-2668
Fax: (877) 405-7940
Hours of Operation: Monday-Friday: 8AM-11PM (ET)
Saturday: 8AM-6:30PM (ET) | Sunday: Closed

Kroger Specialty Pharmacy
Phone: (800) 228-3643
Fax: (866) 539-1092
Hours of Operation: Monday-Friday: 7AM-7PM (CT)
Saturday-Sunday: Closed

Mail-Meds Clinical Pharmacy
Phone: (800) 939-2022
Fax: (855) 523-0910
Hours of Operation: Monday-Friday: 8:30AM-5:30PM (ET)
Saturday-Sunday: Closed

Meijer Specialty
Phone: (855) 263-4537
Fax: (877) 222-5036
Hours of Operation: Monday-Friday: 9AM-10PM (ET)
Saturday: 9AM-5PM (ET) | Sunday: Closed

Optum Specialty Pharmacy
Phone: (855) 427-4682
Fax: (877) 342-4596
Hours of Operation: Monday-Friday: 8:30AM-10PM (ET)
Saturday: 9AM-5:30PM (ET) | Sunday: Closed

Specialty distributor network for CABENUVA

ASD Specialty Healthcare
(800) 746-6273

Besse Medical
(800) 543-2111

Cardinal Health Specialty
(866) 476-1340

CuraScript Specialty Distribution
(800) 942-5999

McKesson Plasma and Biologics
(877) 625-2566

McKesson Specialty Health
(800) 482-6700

All GSK-authorized wholesalers: eligible to access CABENUVA, provided they service eligible customer classes of trade.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions:

- Hypersensitivity reactions, including cases of drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported during postmarketing experience with rilpivirine-containing regimens. While some skin reactions were accompanied by constitutional symptoms such as fever, other skin reactions were associated with organ dysfunctions, including elevations in hepatic serum biochemistries
- Serious or severe hypersensitivity reactions have been reported in association with other integrase inhibitors and could occur with CABENUVA
- Discontinue CABENUVA immediately if signs or symptoms of hypersensitivity reactions develop. Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated. Cabotegravir and rilpivirine oral lead-in may be used to help identify patients who may be at risk of a hypersensitivity reaction

Please see additional Important Safety Information throughout and click for full Prescribing Information for CABENUVA.

ViiVConnect

CABENUVA
cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
extended-release injectable suspensions



600-mg/900-mg kit*

(for use in every-2-month and once-monthly dosing schedules)†

Two extended-release injectable suspensions: cabotegravir 600 mg/3 mL & rilpivirine 900 mg/3 mL

NDC – 49702-240-15

300 billing units



400-mg/600-mg kit*

(for use in once-monthly dosing schedule)†

Two extended-release injectable suspensions: cabotegravir 400 mg/2 mL & rilpivirine 600 mg/2 mL

NDC – 49702-253-15

200 billing units

*The CABENUVA dosing kits have standard 1.5-inch safety needles. If 2-inch safety needles are required to reach the gluteus muscle, please order by visiting: http://www.fisherhealthcare.com/2inchsafetyneedle.

†Please click for Prescribing Information for CABENUVA for more information on dosing and administration.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Post-Injection Reactions:

- Serious post-injection reactions (reported in less than 1% of subjects) were reported within minutes after the injection of rilpivirine, including dyspnea, bronchospasm, agitation, abdominal cramping, rash/urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest). These events may have been associated with accidental intravenous administration and began to resolve within a few minutes after the injection

Please see additional Important Safety Information throughout and click for full Prescribing Information for CABENUVA.

ViiVConnect

CABENUVA
cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
extended-release injectable suspensions

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Post-Injection Reactions (cont'd):

- Carefully follow the Instructions for Use when preparing and administering CABENUVA. The suspensions should be injected slowly via intramuscular injection and avoid accidental intravenous administration. Observe patients briefly (approximately 10 minutes) after the injection. If a post-injection reaction occurs, monitor and treat as clinically indicated

Hepatotoxicity:

- Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-existing hepatic disease or identifiable risk factors
- Patients with underlying liver disease or marked elevations in transaminases prior to treatment may be at increased risk for worsening or development of transaminase elevations
- Monitoring of liver chemistries is recommended and treatment with CABENUVA should be discontinued if hepatotoxicity is suspected

Depressive Disorders:

- Depressive disorders (including depressed mood, depression, major depression, mood altered, mood swings, dysphoria, negative thoughts, suicidal ideation or attempt) have been reported with CABENUVA or the individual products
- Promptly evaluate patients with depressive symptoms

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions:

- The concomitant use of CABENUVA and other drugs may result in known or potentially significant drug interactions (see Contraindications and Drug Interactions)
- Rilpivirine doses 3 and 12 times higher than the recommended oral dosage can prolong the QTc interval
- CABENUVA should be used with caution in combination with drugs with a known risk of Torsade de Pointes

Long-Acting Properties and Potential Associated Risks with CABENUVA:

- Residual concentrations of cabotegravir and rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer). Select appropriate patients who agree to the required monthly or every-2-month injection dosing schedule because non-adherence could lead to loss of virologic response and development of resistance
- To minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen no later than 1 month after the final injection doses of CABENUVA when dosed monthly and no later than 2 months after the final injections of CABENUVA when dosed every 2 months. If virologic failure is suspected, switch the patient to an alternative regimen as soon as possible

Long-Acting Properties and Potential Associated Risks with CABENUVA (cont'd):

ADVERSE REACTIONS

- The most common adverse reactions in adults (incidence ≥2%, all grades) treated with CABENUVA were injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash
- The safety of CABENUVA in adolescents is expected to be similar to adults

DRUG INTERACTIONS

- Refer to the applicable full Prescribing Information for important drug interactions with CABENUVA, VOCABRIA (cabotegravir), or EDURANT (rilpivirine)
- Because CABENUVA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended
- Drugs that are strong inducers of UGT1A1 or UGT1A9 are expected to decrease the plasma concentrations of cabotegravir. Drugs that induce or inhibit CYP3A may affect the plasma concentrations of rilpivirine
- CABENUVA should be used with caution in combination with drugs with a known risk of Torsade de Pointes

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** There are insufficient human data on the use of CABENUVA during pregnancy to adequately assess a drug-associated risk for birth defects and miscarriage. Discuss the benefit-risk of using CABENUVA during pregnancy and conception and consider that cabotegravir and rilpivirine are detected in systemic circulation for up to 12 months or longer after discontinuing injections of CABENUVA. An Antiretroviral Pregnancy Registry has been established
- **Lactation:** The CDC recommends that HIV-1–infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. Breastfeeding is also not recommended due to the potential for developing viral resistance in HIV-positive infants, adverse reactions in a breastfed infant, and detectable cabotegravir and rilpivirine concentrations in systemic circulation for up to 12 months or longer after discontinuing injections of CABENUVA

Please see additional Important Safety Information throughout and click for full Prescribing Information for CABENUVA.

ViiVConnect

CABENUVA
cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
extended-release injectable suspensions